ID: ALA3144022

Max Phase: Preclinical

Molecular Formula: C9H13N2O8PS

Molecular Weight: 340.25

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC(=O)c1csc([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)n1

Standard InChI:  InChI=1S/C9H13N2O8PS/c10-8(14)3-2-21-9(11-3)7-6(13)5(12)4(19-7)1-18-20(15,16)17/h2,4-7,12-13H,1H2,(H2,10,14)(H2,15,16,17)/t4-,5-,6-,7-/m1/s1

Standard InChI Key:  XDDGVTBJYGSVPM-DBRKOABJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 340.25

Molecular Weight (Monoisotopic): 340.0130

AlogP: -1.49

#Rotatable Bonds: 5

Polar Surface Area: 172.43

Molecular Species: ACID

HBA: 8

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 1.23

CX Basic pKa:

CX LogP: -2.16

CX LogD: -5.68

Aromatic Rings: 1

Heavy Atoms: 21

QED Weighted: 0.40

Np Likeness Score: 0.93

References

1. Gebeyehu G, Marquez VE, Van Cott A, Cooney DA, Kelley JA, Jayaram HN, Ahluwalia GS, Dion RL, Wilson YA, Johns DG..  (1985)  Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase.,  28  (1): [PMID:2856943] [10.1021/jm00379a018]

2. Goldstein BM, Bell JE, Marquez VE..  (1990)  Dehydrogenase binding by tiazofurin anabolites.,  33  (4): [PMID:1969483] [10.1021/jm00166a007]

3. Srivastava PC, Revankar GR, Robins RK..  (1984)  Synthesis and biological activity of nucleosides and nucleotides related to the antitumor agent 2-beta-D-ribofuranosylthiazole-4-carboxamide.,  27  (3): [PMID:6699872] [10.1021/jm00369a006]

Source

Source(1):

• Scientific Literature